Fig. 8: UF146 prolongs the survival of AML mice.

a The survival of AE9a- (n ≥ 15) or MLL-AF9-driven (n ≥ 14) AML mice treated with UF146 or the vehicle. b The Wright’s staining of PB isolated from the AE9a (at week 3)- or MLL-AF9 (at week 4)-driven AML mice treated with UF146 or the vehicle. c The WBC counts in the AE9a- or MLL-AF9-driven AML mice treated with UF146 or the vehicle (n ≥ 7). d, e The representative flow cytometry analysis profiles (d) and quantification analysis (e) of GFP⁺ Mac-1⁺ PB cells of UF146- or the vehicle-treated mice (n ≥ 8). f The strategy of the AML patient cell-derived xenograft transplantation model. g The survival curves of the UF146- or the vehicle-treated B-NDG mice (n ≥ 6) transplanted with the primary AML-M4 cells. h, i The Wright’s (h) and HE (i) staining analysis of BM and spleen cells isolated from UF146- or the vehicle-treated recipients that were transplanted with the primary AML-M4 cells were performed 2 weeks after transplantation. j, k The flow cytometry analysis of human CD45⁺ (hCD45⁺) (j), hCD45⁺human CD34⁺ (hCD34⁺) (k) BM cells isolated from UF146- or the vehicle-treated recipients transplanted with the primary AML-M4 cells (n = 3). l Flow cytometry analysis of hCD45⁺ PB cells from UF146- or vehicle-treated recipient mice transplanted with the primary AML-M2 cells (n = 4). Data are all presented as means ± SD; *P < 0.05, **P < 0.01, ***P < 0.001.